bristol-myers glp-1 receptor agonist products Agonists Reduce Adverse Cardiovascular Outcomes, Improve Survival GLP-1 Receptor Agonists as Treatments

doi: 10.1186/1741-7015-11-8 26 HayDLChenSLutzTAParkesDGRothJD

[DOI] [PubMed] [Google Scholar] 30.Buffa R., Capella C., Fontana P., Usellini L., Solcia E

Personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or severe gastrointestinal conditions like gastroparesis may rule out tirzepatide and similar GLP-1 based therapies

Greater effectiveness in blood glucose control appears to result from activation of both receptors

GLP-1 analogs and DPP-4 inhibitors in type 2 diabetes therapy: Review of head-to-head clinical trials

As a result of this growth, it is essential to explore and understand the impact of these medications on gastrointestinal procedures, mainly esophagogastroduodenoscopies (EGDs) and colonoscopies